ArriVent BioPharma, Inc.
No SEC Form 4 filings for $AVBP in the last 30 days.
See all $AVBP insider activity →Analysts raised ArriVent BioPharma's 12-month price target from $22.91 to $24, suggesting 14% upside. The consensus rating remains 'Buy' among 12 analysts. Forecasts range from $15 to $30 per share, according to estimates.
ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 · 44.8% ORR at 6mg/kg dose in late-line CRC patients · ARR-217 was generally well-tolerated · ArriVent to host virtual webinar on Mo
ArriVent BioPharma (AVBP) reported Phase 1 results for ARR-217, showing a 44.8% response rate in colorectal cancer patients at a 6mg/kg dose. The drug was generally well-tolerated. ArriVent plans a Phase 1b dose optimization study, with data expected in 2027. ARR-217 is a cadherin-17-targeting antibody-drug conjugate developed with Lepu Biopharma.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning AVBP (ArriVent BioPharma, Inc.). Coverage has skewed bullish: 8 bullish, 0 neutral, and 0 bearish.
Analysts raised ArriVent BioPharma's 12-month price target from $22.91 to $24, suggesting 14% upside. The consensus rating remains 'Buy' among 12 analysts. Forecasts range from $15 to $30 per share, according to estimates.
Positive Phase 1 results are likely to lift AVBP stock as investors price in potential efficacy and future trial milestones.
Positive Phase 1 results may lift AVBP as investors anticipate further development and potential market potential.
Positive early-phase data could lift AVBP on expectations of further development and potential partnerships.
Strong early‑stage data may boost investor confidence and drive short‑term price appreciation.
AlphAI scores every news story that mentions AVBP with an AI model for sentiment and relevance, and aggregates insider trades from ArriVent BioPharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts raised ArriVent BioPharma's 12-month price target from $22.91 to $24, suggesting 14% upside. The consensus rating remains 'Buy' among 12 analysts. Forecasts range from $15 to $30 per share, according to estimates.
2 min readArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 · 44.8% ORR at 6mg/kg dose in late-line CRC patients · ARR-217 was generally well-tolerated · ArriVent to host virtual webinar on Mo
2 min readArriVent BioPharma (AVBP) reported Phase 1 results for ARR-217, showing a 44.8% response rate in colorectal cancer patients at a 6mg/kg dose. The drug was generally well-tolerated. ArriVent plans a Phase 1b dose optimization study, with data expected in 2027. ARR-217 is a cadherin-17-targeting antibody-drug conjugate developed with Lepu Biopharma.
2 min readArriVent BioPharma (Nasdaq: AVBP) announced that initial safety and efficacy data from its Phase 1 study of ARR-217, a CDH17-targeted ADC for gastrointestinal cancers, will be presented at ESMO Congress 2026. The company will host a webinar on October 26, 2026, to discuss the data. ARR-217 is ArriVent's lead clinical candidate, obtained via a collaboration with Lepu Biopharma.
2 min readArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer NEWTOWN SQUARE, PA, October 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedic
2 min readArriVent BioPharma (AVBP) reported Phase 1b trial results for firmonertinib, showing 43% and 68% response rates at different doses in EGFR PACC-mutant NSCLC. The drug demonstrated intracranial activity and manageable safety. ArriVent is advancing a Phase 3 trial (ALPACCA) for this underserved lung cancer population, with no current standard treatment.
2 min readArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002 NEWTOWN SQUARE, PA, October 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerat
1 min readArriVent BioPharma (AVBP) dosed the first patient in a Phase 1 trial for ARR-002, a dual-target ADC for ovarian and endometrial cancer. The company licensed ARR-002 to Allist for Greater China. ARR-002 targets MUC16 and NaPi2b, aiming to overcome limitations of single-target ADCs. Preclinical data showed improved activity and stability. ArriVent's pipeline includes lung and gastrointestinal cancer programs.
2 min readHC Wainwright & Co. kept a Buy rating and $27 price target on ArriVent BioPharma, implying a 59.9% upside from its Oct 7 close. The firm cited positive clinical data from the FURVENT trial and promising pipeline developments, including ARR-217, for its outlook.
1 min readShanghai Allist Pharmaceuticals (SS:688578) shares dropped 20% after its U.S. partner ArriVent Biopharma (NASDAQ:AVBP) reported that a late-stage trial of lung cancer drug firmonertinib failed to meet its primary endpoint. The drug did not show a statistically significant improvement in progression-free survival for patients with non-small cell lung cancer.
2 min read
